دورية أكاديمية

A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study.

التفاصيل البيبلوغرافية
العنوان: A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study.
المؤلفون: Nakai, Y, Isayama, H, Sasaki, T, Sasahira, N, Tsujino, T, Toda, N, Kogure, H, Matsubara, S, Ito, Y, Togawa, O, Arizumi, T, Hirano, K, Tada, M, Omata, M, Koike, K
المصدر: British Journal of Cancer; 6/5/2012, Vol. 106 Issue 12, p1934-1939, 6p, 2 Diagrams, 3 Charts, 2 Graphs
مصطلحات موضوعية: CANCER research, PANCREATIC cancer treatment, NUCLEOSIDES, PANCREATIC cancer, CANCER patients, CANCER invasiveness, RANDOMIZED controlled trials, THERAPEUTICS
مستخلص: Background:This randomised phase II trial compared gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer.Methods:Patients were randomly assigned to 4-week treatment with gemcitabine alone (1000, mg m−2 gemcitabine by 30-min infusion on days 1, 8, and 15) or gemcitabine and S-1 combination therapy (1000, mg m−2 gemcitabine by 30-min infusion on days 1 and 15 and 40 mg m−2 S-1 orally twice daily on days 1-15). The primary end point was progression-free survival (PFS).Results:Between July 2006 and February 2009, 106 patients were enrolled. The PFS in gemcitabine and S-1 combination arm was significantly longer than in gemcitabine arm (5.4 vs 3.6 months), with a hazard ratio of 0.64 (P=0.036). Overall survival (OS) for gemcitabine and S-1 combination was longer than that for gemcitabine monotherapy (13.5 vs 8.8 months), with a hazard ratio of 0.72 (P=0.104). Overall, grade 3 or 4 adverse events were similar in both arms.Conclusion:Gemcitabine and S-1 combination therapy demonstrated longer PFS in advanced pancreatic cancer. Improved OS duration of 4.7 months was found for gemcitabine and S-1 combination therapy, though this was not statistically significant. [ABSTRACT FROM AUTHOR]
Copyright of British Journal of Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:00070920
DOI:10.1038/bjc.2012.183